NASDAQ:BNTX • US09075V1026
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIONTECH SE-ADR (BNTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | TD Cowen | Maintains | Hold -> Hold |
| 2026-03-11 | BMO Capital | Maintains | Outperform -> Outperform |
| 2026-03-11 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-11 | Citigroup | Maintains | Buy -> Buy |
| 2026-03-10 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-16 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-06 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-23 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-10-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-22 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-05 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-16 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-03 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-05-29 | Goldman Sachs | Initiate | Neutral |
| 2025-05-22 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.819B -77.94% | 2.751B -27.96% | 2.87B 4.32% | 2.292B -20.14% | 2.401B 4.76% | 2.618B 9.04% | 3.09B 18.03% | 3.745B 21.20% | 5.191B 38.61% | 6.054B 16.62% | 6.59B 8.85% | |
| EBITDA YoY % growth | 1.091B -91.21% | -203.4M -118.64% | 167.1M 182.15% | -899.096M -638.06% | -987.494M -9.83% | 389.85M 139.48% | 651.57M 67.13% | 1.403B 115.33% | 1.981B 41.20% | 2.538B 28.12% | N/A | |
| EBIT YoY % growth | 908M -92.62% | -501.4M -155.22% | -215.7M 56.98% | -1.418B -557.17% | -1.501B -5.86% | -1.372B 8.54% | -697.079M 49.21% | -325.735M 53.27% | 1.025B 414.67% | 1.57B 53.17% | 1.866B 18.85% | |
| Operating Margin | 23.78% | -18.23% | -7.52% | -61.85% | -62.50% | -52.42% | -22.56% | -8.70% | 19.75% | 25.93% | 28.32% | |
| EPS YoY % growth | 3.83 -89.63% | -2.78 -172.58% | -4.70 -69.06% | -3.53 24.94% | -3.35 5.16% | -0.14 95.86% | -1.95 -1,308.54% | -1.61 17.75% | 2.54 258.16% | 4.65 83.20% | 6.27 34.75% |
All data in EUR
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -2.14 -23.57% | -2.33 -45.35% | -0.30 -148.63% | 1.62 229.74% |
| Revenue Q2Q % growth | 182.47M -0.18% | 239.35M -8.22% | 836.83M -44.91% | 1.001B 10.32% |
| EBITDA Q2Q % growth | -564.146M -20.31% | -472.985M -25.63% | 25.285M -97.10% | N/A |
| EBIT Q2Q % growth | -682.723M -33.42% | -588.458M -25.12% | -109.309M -116.69% | 204.35M 246.49% |
All data in EUR
28 analysts have analysed BNTX and the average price target is 140.76 USD. This implies a price increase of 59.22% is expected in the next year compared to the current price of 88.41.
BIONTECH SE-ADR (BNTX) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of BIONTECH SE-ADR (BNTX) is -2.14 USD and the consensus revenue estimate is 182.47M USD.
The consensus rating for BIONTECH SE-ADR (BNTX) is 81.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.